Excessive bone mineral density (BMD) loss has been associated with schizophrenia, but its mechanisms and clinical implications are less clear. The aim of this review was to summarize the risk of osteoporosis and bone fractures in schizophrenia patients. Moreover, we aimed to examine the impact of antipsychoticinduced hyperprolactinemia on bone metabolism.
INTRODUCTION
Schizophrenia is a severe and predominantly chronic-relapsing disorder that is associated with marked functional impairments [1] . Furthermore, schizophrenia has been associated with a greater prevalence of health problems, including obesity, diabetes, metabolic syndrome, cardiovascular diseases, HIV infection, hepatitis, altered pain sensitivity, obstetric complications, dental problems, polydipsia, sexual dysfunction, and osteoporosis, than in the general population [2,3 & ,4]. Of these medical comorbidities, osteoporosis has received attention recently. Osteoporosis, characterized by abnormally low bone mineral density (BMD), is an important comorbidity in schizophrenia, as it can be related to the mental illness or developed due to a third, medical condition, unhealthy lifestyle behaviors or, possibly, the prolactin-elevating effects of antipsychotics [5] .
Although lower BMD among schizophrenia patients was noted earlier [6, 7] , insufficient attention has been paid to this phenomenon. Moreover, the mechanisms, prevention, and clinical management of osteoporosis in schizophrenia patients have been only insufficiently defined. Over the past 5 years, there have been several reviews in this area [8] [9] [10] [11] , including a thorough review by Graham et al. [9] . However, the debate has mainly focused on the effects of antipsychotic-related hyperprolactinemia on BMD. By contrast, no review has specifically focused on the relationship between BMD and schizophrenia since 2007 [12] .
METHODS
In this study, we will review first the definition, measurement, risk factors, and causes of osteoporosis. We will then examine the recent evidence regarding BMD and fracture risk in schizophrenia and examine the impact of antipsychotics on bone metabolism. To this end, we conducted a systematic review, searching PubMed from its inception until April 2012, using the following key words and their synonyms: 'schizophrenia', 'bone', 'osteoporosis', and 'fracture'. Finally, focusing on the most recent and qualitatively best evidence, we will make recommendations for the clinical evaluation and management of osteoporosis in patients with schizophrenia.
RESULTS
In the sections below, we summarize the definition and measurement of osteoporosis as well as its risk factors and causes. In addition, we review the studies that have investigated the association of BMD or fracture risk with schizophrenia, antipsychotic treatment, and prolactin levels.
OSTEOPOROSIS DEFINITION AND MEASUREMENT
Osteoporosis is defined as 'a systemic skeletal disease characterized by low bone density and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture' [13] . Osteoporosis is often described as a 'silent disease', meaning that it commonly is not characterized by overt symptoms, despite being a strong predictor of fractures. Osteoporosis can lead to spinal fractures, hip fractures, and other potentially life-threatening complications [14] . It can impair activities of daily life and is also associated with increased mortality [15] .
The standard method for assessing BMD is dualenergy X-ray absorptiometry (DEXA) [16] . BMD (g/cm 2 ) is usually expressed as a population standard based t-score and a z-score according to the following formula:
(1) t-score ¼ (BMD of the patient -young adult mean BMD)/standard deviation of the BMD of a young adult; (2) z-score ¼ (BMD of the patient -mean BMD of the age and sex-matched group)/standard deviation of the BMD of an age and sex-matched group.
On the basis of this convention, the t-score is used for assessing the patients' bone density compared with standardized peak bone mass and for making a diagnosis of osteoporosis, whereas the z-score is used when comparing the patient with an age and sex-matched general population. According to the WHO definition, a t-score of less than À1 to greater than À2.5 is categorized as osteopenia, and a t-score of À2.5 or less is categorized as osteoporosis [13] . There are also several nonstandard methods to measure BMD. These include singleenergy X-ray absorptiometry (SXA), peripheral dual-energy X-ray absorptiometry (pDXA), dualphoton absorptiometry (DPA), quantitative computed tomography (QCT), and quantitative ultrasound (QUS). QUS is widely used because of the low cost and lack of ionizing radiation. Different from other methods using X-ray, QUS measures broadband ultrasound attenuation (BUA), speed of
KEY POINTS
A higher prevalence of osteoporosis compared with the general population is reported in patients with schizophrenia.
Unhealthy lifestyle behaviors, such as little or no exercise, alcoholism, smoking, undernutrition, and unhealthy diet with deficiencies of calcium and vitamin D contribute to low bone mineral density and elevated fracture risk in schizophrenia.
Antipsychotic-induced hyperprolactinemia has been suggested as one of the mechanisms of low bone mineral density in schizophrenia, but the results are mixed and firm conclusions cannot be drawn at this point.
In order to better examine the relationship between antipsychotics and low bone mineral density, well designed, longitudinal studies are needed, and measurement of bone turnover markers may be helpful.
Until the relationship between hyperprolactinemia and osteoporosis has been better clarified, the main clinical focus should be on prevention and early intervention through promoting healthy diet, exercise, and adequate sun exposure, although hypogonadism associated with hyperprolactinemia should prompt actions to reduce serum prolactin. sound (SOS), and so on, but often results are converted into t-scores or z-scores [17] .
Bone is a dynamic tissue. Throughout life, bone tissue is continually being formed and resorbed. This process is called remodeling, which is under the control of many factors, including sex hormones. In postmenopausal type I osteoporosis, the decline of estrogen levels in women leads to the acceleration of BMD loss, which results from loss of estrogen's bone protective effects [18] . Thus, stable BMD depends on the balance of bone resorption and formation. A number of sensitive and valid bone turnover markers (BTMs) are available that can help measure a patient's bone resorption and bone formation status, and some of them are utilized in clinical practice (Table 1) [16,19,20 & ].
RISK FACTORS FOR AND CAUSES OF OSTEOPOROSIS
Since bone mineralization, formation, and resorption are under the control of multiple physiological processes, many conditions, medications, and lifestyle behaviors have been associated with decreased BMD. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Nine studies used DEXA to assess BMD, and five studies used QUS. Among 11 studies using a control group, 10 (90.9%) found lower BMD in schizophrenia compared with healthy controls in at least one region or at least one patient subgroup. All five studies using reference data found lower BMD in schizophrenia. The magnitude of the differences varied. Some studies reported lower BMD in only one or few of many other measures; some reported that lower BMD was found in most measures.
Four studies also utilized BTMs to assess the bone metabolism status in patients, each finding significant differences from healthy controls, or abnormality, including the one study [33] which did not find significant BMD differences, probably due to the small sample.
FRACTURE RISK IN SCHIZOPHRENIA
Only few studies (N ¼ 4) have focused on fracture risk in schizophrenia. In a Canadian populationbased, administrative database, persons with osteoporotic fractures (n ¼ 15 792) were compared with controls matched for age, sex, ethnicity, and comorbidity (n ¼ 47 289) [45] . Whereas antipsychotics did not significantly increase the risk of osteoporotic fractures, schizophrenia diagnosis did [odds ratio (OR) 2.17, 95% confidence interval (CI) 1.75-2.69]. Somewhat opposing results were obtained in a case-control study using the General Practice Research Database in the UK, which compared 16 341 hip fracture cases with 29 889 matched controls [46] . In this study, hip fracture was associated with schizophrenia (OR 1.73; 95% CI 1.32-2.28), as well as with mostly prolactin-raising first-generation antipsychotics (OR 2.6; 95% CI 2.43-2.78). However, in a multivariate analysis, prolactin-raising antipsychotics were independently associated with hip fracture, whereas this was not the case for schizophrenia. In a Danish case-control study (fracture cases ¼ 124 655, controls ¼ 373 962), focusing on the use of psychotropic medications, antipsychotic use was associated with a small but significant increase in overall fracture risk (OR around 1.2) [47] . Similarly, another case-control study from the UK (n ¼ 44 500) found that both current and prior antipsychotic use and duration of antipsychotic use were associated with a small significant increase (OR 1.3, 1.3, r 2 ¼ 0.88, respectively) of hip/femur fractures after adjustment for possible confounders [48] . Taken together, these results seem to suggest that antipsychotics contribute to a small increase in the risk of fractures. However, results are restricted to database and case-control studies, whereas more definitive, prospective, long-term studies that directly assess relevant confounding variables are missing.
LIFESTYLE AND LOW BONE MINERAL DENSITY IN SCHIZOPHRENIA
Since poor lifestyle behaviors can lower BMD (Table  2) , the greater prevalence and intensity of sedentary lifestyle, staying indoors, and poor diet in schizophrenia [3 & ], which can be related to negative symptoms and poor functioning, may predispose patients to low BMD and fracture risk. In fact, a recent review demonstrated low levels of physical activity in schizophrenia patients and a significant relationship with negative symptoms [49] .
Smoking is an established risk factor for osteoporosis and osteoporotic fracture [50] . A metaanalysis, including 42 studies across 20 nations, confirmed high smoking rates in schizophrenia, finding a weighted average OR for current smoking of 5.9 (95% CI 4.9-5.7) [51] . Mechanisms include alterations in calciotropic hormone metabolism, intestinal calcium absorption, sex hormone regulation, adrenal cortical hormone metabolism, and the various receptor activators [52] .
Excessive alcohol intake is common in schizophrenia. Lifetime alcohol abuse is found in 14.5% of schizophrenia patients, with a rate for alcohol dependence of 14.2% [53] . Alcohol's negative impact on BMD results from direct or indirect adverse effects on bone-forming cells, calcium-regulating hormones, and growth factors [54] . Malnutrition or inappropriate amounts or composition of food intake is also found in schizophrenia. In a study of 25 schizophrenia patients, 25(OH)vitamin D levels were significantly lower than in healthy controls (23.6 AE 2.8 vs. 71.9 AE 8.3; P ¼ 0.001) [33] . In an Austrian study, 25-hydroxy-vitamin D3 deficiency was found in as many as 50.9% of men and in 52.9% of women with schizophrenia [43] . Vitamin D deficiency reflects both lack of vitamin D intake and/or synthesis, being related to poor diet or insufficient sun exposure. Moreover, polydipsia, which is sometimes observed in schizophrenia, can also lead to low BMD, presumably through excessive urinary calcium loss [55] .
An individual's peak bone mass is typically achieved by age 30, and thereafter BMD decreases. Therefore, it is crucial to achieve high peak bone mass through appropriate exercise and nutrition during adolescence and young adulthood. However, unhealthy lifestyle behaviors can already occur in younger patients. Decreased BMD, measured via QUS in 133 women with schizophrenia, was prominent not only in older but also in younger patients (20-24 and 25-29 years old) with shorter illness and antipsychotic medication exposure [44] .
ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA AND BONE METABOLISM
Antipsychotics can inhibit the hypothalamopituitary-gonadal axis and this is partly responsible for low BMD in schizophrenia. Elevated serum prolactin can suppress secretion of gonadotropinreleasing hormone (GnRH) from the hypothalamus. In turn, low GnRH results in a reduced secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, reducing levels of estradiol, progesterone, and testosterone, leading to abnormal bone metabolism similar to type I osteoporosis [11, 41, 56] . The hypothesis that antipsychotic-induced hyperprolactinemia lowers BMD is derived from early observations and has been consistently replicated in patients with usually severe hyperprolactinemia due to medical reasons, such as prolactin-secreting pituitary tumors, which were associated with low testosterone levels and/or significant BMD reductions [57] [58] [59] . Moreover, bone loss was also related to the duration of the hyperprolactinemia [57] . Therefore, it is reasonable to assume that antipsychotic-induced hyperprolactinemia can have the same effect, at least, when reaching a certain physiological threshold that induces hypogonadism. Animal studies support the negative effect of antipsychotics on bone density and formation. A note of caution is required, because this mechanism is not consistent with the hypothesis mentioned above [60, 61] , antipsychotic half-lives are much shorter in rodents, and rodent prolactin physiology also differs from humans.
Results from human studies ( Table 4 [ 38, [40] [41] [42] [43] 56, 62 & ,63-70]) have been inconsistent, possibly due to methodological limitations, the predominantly cross-sectional study design, and small sample sizes. Across 15 studies we identified examining prolactin effect on bone, 13 were crosssectional (n ¼ 1062, mean age 54.2 years, 43.5% men) and only two were prospective (n ¼ 52, mean age 36.3 years, 0% men) ( Table 4 ). The 13 crosssectional studies examined the effect of hyperprolactinemia on bone by correlating BMD or BTM levels with prolactin values, comparing groups with higher vs. lower serum prolactin, high vs. normal prolactin groups, or longer exposure vs. shorter exposure to prolactin-raising antipsychotics; investigating the correlation between prolactin levels and BMD; or comparing prolactin levels between low vs. normal-BMD patient groups. Overall, 8/13 (61.5%) studies found some relationship between hyperprolactinemia and low BMD. Whereas these data seem to point in one direction, the results are less convincing because, even among studies reporting significant associations, this was frequently only one finding among several negative results. These cross-sectional studies contain considerable limitations for a conclusive examination of the prolactin effect on BMD since it may take years for BMD loss to manifest after disruption of normal bone metabolism.
Recent studies have examined the long-term effects of excessive prolactin secretion. For example, Kishimoto et al. [41] found a significant negative correlation between the duration of antipsychotic treatment and the z-score in hyperprolactinemic patients (r 2 ¼ 0.07, P < 0.05). On the contrary, Hummer et al. [43] also found a trend-level negative correlation between duration of treatment and z-score (r 2 ¼ 0.06, P < 0.08) in male patients, but this finding was mainly due to one extreme outlier with a long duration of treatment, and the statistical trend disappeared after excluding this patient.
Given the difficulties of directly assessing the effect of prolactin on BMD, utilization of BTMs that predict future bone density loss and fractures [16] and that may be more sensitive markers of shortterm bone metabolism disruption is a reasonable alternative strategy. Across four cross-sectional studies (n ¼ 521), only one showed an association between prolactin/prolactin-raising antipsychotics and BTM. However, in two small prospective studies (n ¼ 52, mean age 36.3, 0% men), both found a significant negative prolactin effect on BTM after just 1 year.
RECOMMENDATIONS FOR THE MEASUREMENT, PREVENTION, AND TREATMENT OF OSTEOPOROSIS
Low BMD is prevalent in schizophrenia patients. Prevention, early detection, and intervention are required. Proper diet, exercise, and sufficient sun exposure should be encouraged in all patients. Given uncertain prolactin effects on bone metabolism, no specific recommendation can be made at this point. However, other prolactin-related side effects, such as sexual dysfunction, reproductive ", increase; #, decrease; !, no change; AP, alkaline phosphatase; BMD, bone mineral density; BTM, bone turnover marker; BUA, broad ultrasound attenuation; CLO, clozapine; CPZ, chlorpromazine; CTX, cross-linked C-terminal telopeptide of type I collagen; DEXA, dual-energy X-ray absorptiometry; DPD, deoxypyridinoline; FGA, first-generation antipsychotics; FTI, free testosterone index; HAL, haloperidol; HC, healthy control; NA, not applicable; NR, none reported; NTX, urinary N-telopeptide; OC, osteocalcin; OLA, olanzapine; PALI, paliperidone; PRL, prolactin; PYD, pyridinoline; QUS, quantitative ultrasound; RIS, risperidone; SCZ, patients with schizophrenia; SGA, second-generation antipsychotics; SHBG, sex hormone-binding globulin; SoS, speed of sound; t, t-score; z, z-score.
a Subpopulation was extracted.
system dysfunction, a questionable risk increase of breast cancer, and so on [71] , should be screened for, and hyperprolactinemia that leads to physical symptoms should be corrected via use of or switch to prolactin-sparing antipsychotics including olanzapine and, especially, quetiapine, clozapine, and aripiprazole [71, 72] . Aripiprazole is known to decrease prolactin levels, even in combination with prolactin-raising antipsychotics [73, 74] . Finally, standard therapy for osteoporosis, such as bisphosphonates and selective estrogen receptor modulators [24,75,76 & ], should be considered for patients with osteoporosis.
CONCLUSION
Osteoporotic fractures have considerable adverse effects on general health, subjective well being, the ability to engage in healthy lifestyle behaviors, and increased healthcare costs. A higher prevalence of osteoporosis or lower BMD is widely reported in schizophrenia, and needs to be recognized as an important comorbidity. Prevention, early detection, and intervention are required. Although the effect of antipsychotic-induced hyperprolactinemia seems be one contributing factor for low BMD, others, especially those related to poor lifestyle behaviors, may have an even bigger impact. Moreover, since osteoporosis develops over time, sufficiently large, longitudinal studies are required to examine contributors of accelerated BMD loss. To date, there is only limited evidence for the osteoporosis-producing effects of antipsychotics. Better designed studies, including studies utilizing BTM, may further clarify the relationship between antipsychotics and bone metabolism. Until such data are available, the main clinical focus should be on promoting healthy diet and exercise as well as adequate sun exposure. However, if hyperprolactinemia develops, hypogonadism needs to be ruled out via assessment of menses or sex hormone levels, or a change of antipsychotic treatment to a less prolactin-elevating agent should be considered, especially when sexual and/or reproductive system dysfunction is present.
